O

Oncolytics Biotech
D

ONCY

0.50000
USD
0.00
(0.10%)
Post Trading
Volume
4,099
EPS
-0
Div Yield
-
P/E
-2
Market Cap
43,210,796
Related Instruments
ABBV
ABBV
-12.125
(-6.43%)
175.670 USD
AZN
AZN
-3.150
(-4.59%)
64.955 USD
BMY
BMY
-2.170
(-3.95%)
52.790 USD
GSK
GSK
-2.140
(-5.90%)
34.160 USD
JNJ
JNJ
-4.040
(-2.62%)
149.920 USD
LLY
LLY
-11.66
(-1.58%)
726.61 USD
MRK
MRK
-3.250
(-3.95%)
78.960 USD
NVS
NVS
-4.300
(-4.04%)
102.050 USD
PFE
PFE
-1.220
(-5.29%)
21.850 USD
More
News

Title: Oncolytics Biotech

Sector: Healthcare
Industry: Biotechnology
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.